Grifols (GRFS) Income from Continuing Operations (2010 - 2020)
Grifols' (GRFS) quarterly Income from Continuing Operations came in at 330091015.77 in Q1 2020, up 69.41% YoY from 194843192.77 in Q2 2019, and down 55.46% on a QoQ basis from 741176413.24 in Q4 2019.
Grifols (GRFS) Income from Continuing Operations (2010 - 2020) Analysis & Trends
Grifols (GRFS) has 11 years of Income from Continuing Operations data on file, last reported at 330091015.77 in Q1 2020.
- Quarterly Income from Continuing Operations rose 69.41% year-over-year to 330091015.77 in Q1 2020, while the trailing twelve-month figure through Mar 2020 was 2068492905.63 (up 35.91% YoY) and the FY2025 annual result came in at 582021757.35, up 155.71% from the prior year.
- Income from Continuing Operations eased to 330091015.77 in Q1 2020, from 741176413.24 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 882309060.91 in Q4 2017 to a low of 285025600.06 in Q4 2016.
- A 5-year average of 346580489.46 and a median of 260548010.52 in 2018 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2016 — Income from Continuing Operations tumbled 269.94% — and 2017, when it jumped 409.55%.
- Tracing GRFS's Income from Continuing Operations over 5 years: stood at 285025600.06 in 2016, then surged by 409.55% to 882309060.91 in 2017, then declined by 9.06% to 802382283.85 in 2018, then fell by 7.63% to 741176413.24 in 2019, then slumped by 55.46% to 330091015.77 in 2020.
- The last three Income from Continuing Operations figures came in at 330091015.77 (Q1 2020), 741176413.24 (Q4 2019), and 194843192.77 (Q1 2019), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 3.26 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 2.51 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 2.38 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -10.50 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -246.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 207.96 Mn |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 330.09 Mn |
| Dec 31, 2019 | 741.18 Mn |
| Mar 31, 2019 | 194.84 Mn |
| Dec 31, 2018 | 802.38 Mn |
| Jun 30, 2018 | 260.55 Mn |
| Mar 31, 2018 | 264.14 Mn |
| Dec 31, 2017 | 882.31 Mn |
| Jun 30, 2017 | 255.10 Mn |
| Mar 31, 2017 | 247.88 Mn |
| Dec 31, 2016 | -285.03 Mn |
| Sep 30, 2016 | 227.94 Mn |
| Jun 30, 2016 | 202.82 Mn |
| Mar 31, 2016 | 381.34 Mn |
| Dec 31, 2015 | -77.05 Mn |
| Sep 30, 2015 | 227.51 Mn |
| Jun 30, 2015 | 215.29 Mn |
| Mar 31, 2015 | 305.44 Mn |
| Dec 31, 2014 | -531.60 Mn |
| Sep 30, 2014 | 180.98 Mn |
| Jun 30, 2014 | 141,763.74 |